Trubion Pharmaceuticals Provides Announcement Dates for First-Quarter Earnings Conference Call

SEATTLE, May 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced it plans to issue earnings results for the first quarter ended March 31, 2008, after the close of market on May 8, 2008. The company's earnings conference call will take place May 8, 2008, at 2 p.m. PDT (5 p.m. EDT).

Both live events will be available for viewing on Trubion's website at

First-Quarter Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, May 8, 2008

Participants are invited to call 1(877) 545-1488 or 1 (719) 325-4899. A replay of the discussion will be available after 5 p.m. PDT / 8 p.m. EDT by visiting Trubion's website or by calling 1(888) 203-1112 or 1 (719) 457-0820, and entering 7602146. The replay will be available until midnight, Monday, May 12.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website:

SOURCE Trubion Pharmaceuticals, Inc.